Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon in Diabetic Foot Ulcers
NCT00820703Phase 2Terminated
- Sponsor
- OcuNexus Therapeutics
- Start
- Apr 2009
- Primary completion
- Nov 2009
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of lufepirsen in diabetic foot ulcer (DFU), sponsored by OcuNexus Therapeutics. Started Apr 2009; status: terminated.
02
Drugs
lufepirsen
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT00820703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820703.